The global pandemic has ushered in extraordinary roadblocks for the pharmaceutical industry. Practitioners and litigants are battling with unforeseen hurdles as they navigate FDA approval schedules, filing deadlines and launch dates, and practicing law in the virtual courtroom.
You asked, we listened.
In response, we are excited to introduce ACI’s Paragraph IV on Virtual Trial: COVID–19 Edition, a new virtual conference designed to guide you through the many procedural dilemmas that ANDA litigators are experiencing as a result of the novel coronavirus. This special one-day event will address and provide solutions to coronavirus-related disruptions to Hatch-Waxman litigation.
MEET THE CO-CHAIRS
Senior Vice President, Intellectual Property
Vice President of IP, North America
Fireside Chat with The Federal Circuit
Hon. Kathleen M. O’Malley
United States Circuit Judge
Hon. Mary Pat Thynge
Chief Magistrate Judge
United States Federal District Court, District of Delaware
Spotlight on the USPTO
Hon. Jacqueline D. Wright Bonilla
Deputy Chief Administrative Patent Judge
Patent Trial and Appeal Board
U.S. Patent and Trademark Office
Virtual Courtroom: Navigating Paragraph IV Litigating from Home
Ryan M. Daniel
Chief Patent Counsel, Region North America
Fresenius Kabi USA, LLC
Impact to Motion Practice
Stephanie L. Donahue
Senior Director, Patent Litigation